Physician profile
Maria Basile
NPI 1851595839
$1,279.95
in general payments reported to CMS, 2019-2025
12 companies · $317 in 2025
The $317 reported for 2025 was less than what a typical Ophthalmology provider received nationally (typical 2025 total: $384).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $237 · 2020: $13.17 · 2021: $24.17 · 2023: $231 · 2024: $458 · 2025: $317.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $988 · Education: $17.84.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $987.86 |
| Education | $17.84 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alcon Vision LLC | $240.03 | 2024 | Clareon |
| Tarsus Pharmaceuticals, INC. | $207.88 | 2024-2025 | Xdemvy |
| Sun Pharmaceutical Industries INC. | $206.06 | 2019-2025 | Cequa |
| Carl Zeiss Meditec Cataract Technology INC. | $192.37 | 2023 | |
| Allergan, INC. | $166.83 | 2019 | |
| Bausch & Lomb Americas INC. | $79.74 | 2023-2025 | Miebo, Xiidra, Vyzulta |
| Johnson & Johnson Surgical Vision, INC. | $59.60 | 2024 | Tecnis Simplicity |
| Thea Pharma INC. | $47.01 | 2024-2025 | Iyuzeh |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $24.17 | 2021 | |
| Shire North American Group INC | $23.97 | 2019 | |
| Astellas Pharma US INC | $19.12 | 2024 | Izervay |
| Eyevance Pharmaceuticals LLC | $13.17 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Maria Basile listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.